The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

novonordisk.de

About Novo Nordisk

Novo Nordisk is a global healthcare company that specializes in diabetes care. The company provides medical care for people with serious chronic diseases. It is based in Mainz, Germany.

Novo Nordisk Headquarter Location

Brucknerstrasse 1

Mainz, 55127,

Germany

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Novo Nordisk

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Novo Nordisk is included in 3 Expert Collections, including Diabetes.

D

Diabetes

1,750 items

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

D

Digital Health

410 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

Novo Nordisk Patents

Novo Nordisk has filed 101 patents.

The 3 most popular patent topics include:

  • Drug delivery devices
  • Diabetes
  • Medical equipment
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/15/2020

5/24/2022

Graphical projections, Technical drawing, Roadsters, Light machine guns, Cephalopod zootomy

Grant

Application Date

7/15/2020

Grant Date

5/24/2022

Title

Related Topics

Graphical projections, Technical drawing, Roadsters, Light machine guns, Cephalopod zootomy

Status

Grant

Latest Novo Nordisk News

A massive market beckons, but Novo CEO sees shared purpose

May 27, 2022

The race to meet sudden, stratospheric demand for new anti-obesity meds is hotting up, but Novo Nordisk (NOV: N) CEO Lars Fruergaard Jørgensen takes a collegiate approach. According to analysts, the global market for obesity treatments is set to be worth $27 billion by 2028, growing annually at a blistering average of 17%. Such swollen forecasts are in no small part the result of R&D investments made by Novo Nordisk, which leads the way in… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK

Novo Nordisk Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Novo Nordisk Rank

  • Where is Novo Nordisk's headquarters?

    Novo Nordisk's headquarters is located at Brucknerstrasse 1, Mainz.

  • Who are Novo Nordisk's competitors?

    Competitors of Novo Nordisk include Merck KGaA.

You May Also Like

L
Lilly

Lilly is a pharmaceutical company. The company focuses on diabetes, cancer, immunology, pain, and neurodegeneration drugs. It is based in Toronto, Ontario.

Novartis Logo
Novartis

Novartis (NYSE: NVS) is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. Focusing solely on healthcare, Novartis offers a diversified portfolio to meet these needs including medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools, and consumer health products.

Sanofi Logo
Sanofi

Sanofi (Euronext: SAN) (NYSE: SNY) engages in the research, production, and distribution of pharmaceutical products in the prescription market, as well as over-the-counter medication. The company covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines.

T
Takeda Pharmaceutical

Takeda Pharmaceutical (TYO: 4502) (NYSE: TAK) is a research-based, global pharmaceutical company.

Johnson & Johnson Logo
Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a multi-national manufacturer of pharmaceutical, diagnostic, therapeutic, surgical, and biotechnology products, as well as personal hygiene products.

M
Merck KGaA

Merck Group (FWB: MRK), aka Merck KGaA, is a science and technology company in the healthcare, life science, and performance materials businesses. The company develops biopharmaceutical therapies to treat cancer or multiple sclerosis, systems for scientific research and production, liquid crystals for smartphones and LCD televisions and more. Its former subsidiary Merck & Co. (NYSE: MRK) is a separate independent company.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.